Microarchitecture, but Not Bone Mechanical Properties, Is Rescued with Growth Hormone Treatment in a Mouse Model of Growth Hormone Deficiency

Table 3

Mechanical properties in GH-sufficient (GHS), GH-deficient (GHD), early treatment (early; daily GH injections from age 21 to 60 days), late treatment (late; daily GH injections from age 35 to 60 days), and saline control (saline; daily saline injections from age 21 to 60 days). Mean and standard errors are reported, and the coefficient of varation (CV%). *𝑃≤0.05, **𝑃≤0.001 versus GHS, ⁺𝑃≤0.05, ⁺⁺𝑃≤0.001 versus GHD.

Group	Femur flexural rigidity; (N · mm^2)	Vertebra axial rigidity; (N)	Vertebra trabecular apparent E; (MPa)
GHS	3021.2±156.6	7856.1±289.2	2463.5±209.8
GHD	1006.9±32.3 **	4321.9±167.8 **	1545.4±185.3 *
Early	1432.5±67.4^**+	5757.7±183.9^**++	2409.0±210.5^+
Late	1439.1±105.5^**+	5373.7±239.2^**+	1889.6±116.3
Saline	1037.2±67.4	4348.8±208.0	1669.2±286.1
CV%	16.1%	12.0%	30.8%